Trial Profile

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDX 2001 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors IsoTis OrthoBiologics

Most Recent Events

05 May 2025 According to OPKO Health media release, MDX2001 advanced to the fourth dose level in its Phase 1 clinical trial.
17 Sep 2024 Trial design were presented at the 49th European Society for Medical Oncology Congress.
07 Aug 2024 According to OPKO Health media release, the phase 1 open-label trial is expected to enroll 45 cancer patients with a variety of solid tumors at six clinical trial sites.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com